UBS O'Connor’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

UBS O'Connor’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-775,000	Closed	-$58.3M	–	1063
2022 Q2	$58.3M	Buy	+775,000	New	+$34.4M	0.61%	28
2019 Q4	–	Sell	-39,000	Closed	-$1.47M	–	380
2019 Q3	$1.47M	Buy	+39,000	New	+$1.7M	0.04%	189

UBS O'Connor's TPTX Position: Q3 2022 in Review

UBS O'Connor sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 775,000 shares — an estimated $58.3M sold.

UBS O'Connor first reported a position in TPTX in Q3 2019 and held it in 2 quarters. The position peaked at $58.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

UBS O'Connor reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 775,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $58.3M.
UBS O'Connor first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
UBS O'Connor's Turning Point Therapeutics, Inc. Common Stock position peaked at $58.3M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.